Vol 15, No 3 (2019)
Case report
Published online: 2019-06-26
The usefulness of an 18F-FDG-PET/MR examination in a patient with rectal and breast cancer. A case report
Oncol Clin Pract 2019;15(3):180-184.
Abstract
Recently, we have gained access to innovative radiological and metabolic examination methods. One of these methods is PET/MRI with fluorodeoxyglucose (18F-FDG) tracer. Performing this innovative examination in a 69-year-old woman with diagnosed rectal cancer brought additional benefits. The use of PET/MRI resulted in precise clinical staging, the detection of a synchronous early-stage right breast cancer, and in the optimisation of treatment of both cancers. To date, diagnostic guidelines concerning rectal and breast cancers do not recommend the use of functional imaging for routine imaging.
Keywords: PET/MRrectal cancerbreast cancer
References
- Battersby N, How P, Moran B, et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model. Annals of Surgery. 2016; 263(4): 751–760.
- Bujko K, Herman R, Pałucki J et al. Rak odbytnicy, aktualizacja na dzień 02.12.2015. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Tom I. Krzakowski M, Warzocha K et al. (ed.). Via Medica, Gdańsk 2013; 199 .
- NCCN Clinical Practice Guidelines in Oncology, Rectal Cancer, Version 3.2018.
- Sasaki K, Kawasaki H, Sato M, et al. Impact of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer. Dig Surg. 2017; 34(1): 60–67.
- Brush J, Boyd K, Chappell F, et al. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess. 2011; 15(35): 1–192, iii.
- Magometschnigg HF, Baltzer PA, Fueger B, et al. Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T. Eur J Nucl Med Mol Imaging. 2015; 42(11): 1656–1665.
- Vercher-Conejero JL, Pelegrí-Martinez L, Lopez-Aznar D, et al. Positron emission tomography in breast cancer. Diagnostics (Basel). 2015; 5(1): 61–83.
- Huzarski T, Górecka-Szyld B, Huzarska J, et al. Polish Hereditary Breast Cancer Study Group. Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. Hered Cancer Clin Pract. 2017; 15: 4.
- Jacobs L, Meek DB, van Heukelom J, et al. Comparison of MRI and colonoscopy in determining tumor height in rectal cancer. United European Gastroenterol J. 2018; 6(1): 131–137.
- Dimitriou N, Michail O, Moris D, et al. Low rectal cancer: Sphincter preserving techniques-selection of patients, techniques and outcomes. World J Gastrointest Oncol. 2015; 7(7): 55–70.
- Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005; 23(33): 8469–8476.
- Kowalski ES, Cohen JD, Snider JW, et al. Positron emission tomography/computed tomography (PET/CT) in the initial evaluation of women with nonmetastatic breast cancer can frequently alter management. Int J Radiat Oncol Biol Phys. 2017; 99(2): E25–E26.